Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

IEX · Q4 2025 Earnings

IDEX Corporation

Reported February 4, 2026

30-second summary

Q4 adjusted EPS of $2.10 and organic sales +1% beat the implied Q4 guide ($1.84–$1.89), driving FY25 adjusted EPS to $7.95 — $0.04 above the high end of the narrowed October range. But FY26 guidance lands at $8.15–$8.35 (low-to-mid single digit growth) on 1–2% organic sales, with management explicitly stating "we are not seeing an inflection point in activity." The platform thesis is intact (HST organic +5% / reported +9%, total IDEX organic orders +16% with HST organic orders +34%); the cyclical recovery thesis is being pushed out yet another quarter.

Headline numbers

EPS

Q4 FY2025

$2.10

Revenue

Q4 FY2025

$0.90B

+4.0% YoY

Gross margin

Q4 FY2025

43.1%

Free cash flow

Q4 FY2025

$0.19B

Operating margin

Q4 FY2025

20.4%

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$0.90B	+4.0%	$0.88B	+2.3%
EPS	$2.10	—	$2.03	+3.4%
Gross margin	43.1%	—	44.5%	-140bps
Operating margin	20.4%	—	21.1%	-70bps
Free cash flow	$0.19B	—	$0.19B	+0.7%

Guidance

FY2025 EPS beat prior guidance; FY2026 guidance introduced with low-single-digit EPS growth and flattish organic sales, reflecting modest operational momentum offset by HST mid-single-digit growth tempered by FMT flatness and FSTP decline.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Adjusted Diluted EPS	FY 2025	$7.86 - $7.91	$7.95	+$0.04-$0.09 above guide	Beat

New guidance

Metric	Period	Guide	YoY
Adjusted Diluted EPS	Q1 FY2026	$1.73 to $1.78	—
Adjusted Diluted EPS	FY 2026	$8.15 to $8.35	+2.5-4.5% YoY
Organic Sales Growth	Q1 FY2026	approximately 1%	approximately 1% YoY
Organic Sales Growth	FY 2026	1% to 2%	1-2% YoY
Adjusted EBITDA Margin	Q1 FY2026	approximately 24.5%	—
Adjusted EBITDA Margin	FY 2026	26.5% to 27.0%	—
Effective Tax Rate	FY 2026	approximately 24%	—

Reaffirmed unchanged this quarter: Organic Sales Growth (approximately 1%)

Segment KPIs

Q4 FY2025

Segment	Q4 FY2025	YoY
Health & Science Technologies	$0.408B	+9.3%
Fluid & Metering Technologies	$0.306B	+2.1%
Fire & Safety/Diversified Products	$0.188B	-2.7%

Other KPIs

Q4 FY2025

Segment	Q4 FY2025
Adjusted EBITDA Margin	26.8%
Orders	$979.2 million
Organic Orders Growth	16%
Organic Sales Growth	1%
Operating Cash Flow	$209.5 million
Free Cash Flow Conversion	121%
HST Adjusted EBITDA Margin	27.0%
FMT Adjusted EBITDA Margin	31.4%

Management tone

Q1 2025 platform-build execution → Q2 2025 policy-whiplash reset → Q3 2025 operational discipline and capital return → Q4 2025 cautious 2026 framing with no inflection conceded.

The "we don't see an inflection" line is now hard policy, not commentary. Q2 framed the slowdown as a policy event with July inflection signs. Q3 extended the horizon into 2026. This quarter shuts the door: "we are not seeing an inflection point in activity, and our guidance reflects this reality." The FY26 organic guide of 1–2% is essentially Q4's 1% carried forward with marginal optimism, and the Q1 ~1% number explicitly back-loads any improvement. After three consecutive quarters of "the recovery is just around the corner," management has stopped underwriting that view in the numbers.

Cost optimization recedes; growth platforms take the center. Q3 disclosed the $60M+ FY25 platform optimization savings as the bridge to FY26 margin expansion. Per CFO this quarter, ~$20M of that $60M was temporary and is being allowed back into FY26 results to fund 80/20-informed reinvestment in growth areas. Management pivots to "working across integrated business units is a meaningful expansion of our source code." The FY26 EBITDA margin band (26.5–27.0%) sitting on top of FY25's 26.8% says the savings are largely being reinvested into cross-unit platform work rather than dropping to the bottom line.

Data center is no longer "emerging" — it's the load-bearing column of HST. Q3 mentioned data center as one of several HST contributors. This quarter, "just under half of the backlog build [is] in very specific data center supportive applications" — meaning the HST mid-single-digit FY26 guide and the +34% HST organic order growth are both leaning hard on a single end-market exposure. Bull case: durable secular. Bear case: concentrated.

M&A doctrine hardens further toward integration. Q3 ruled out large deals in favor of bolt-ons. This quarter goes one step further: "we will focus on the integration of recently acquired businesses and new acquisitions will likely be bolt on in nature" — with explicit reference to "doing the work to chart a roadmap for where IDEX goes next." The strategic posture is now defensively integrative; the deal cadence of 2023–24 is over for the foreseeable future.

Q1 margin profile is framed as seasonal, not a concession. The ~24.5% Q1 adjusted EBITDA margin guide reflects what management explicitly called the "seasonally softest" quarter (ag and water hit by winter; HST/FSDP reset on budget cycles for larger orders). The Q1 EPS guide of $1.73–$1.78 is "relatively flat year over year" per CFO, with management contemplating a typical low-to-mid-single-digit sequential top-line step-up in Q2 and a more pronounced earnings step-up on volume normalization and corporate expense. The story to track is whether the Q2 ramp materializes as guided.

Recurring themes management leaned on this quarter:

HST momentum and data center/semiconductor tailwinds offsetting broader industrial weakness80-20 playbook evolution toward cross-unit platforms and integrated growth modelsIndustrial end markets remain flattish with no clear inflection despite improved macro indicatorsUncertainty around FMT/FSDP recovery dependent on policy moderation and macro stabilizationCapital deployment prioritizing organic investment and bolt-on M&A over larger acquisitionsMargin expansion contingent on price-cost dynamics overcoming volume deleverage headwinds

Risks management surfaced:

Industrial end markets remain under pressure with chemical, energy, and agriculture facing headwindsPolicy uncertainty and potential volatility could delay expected macro recoveryFSDP weakness persisting outside North America in fire and safety with dispensing softness continuingLife sciences growth dependent on academic research funding clarity and China exposure uncertaintyVolume deleverage risk in FMT and FSDP offsetting price and productivity gains

Answers to last quarter's watch list

Q4 implied adjusted EPS math. Q4 adjusted EPS printed $2.10, well above the implied $1.84–$1.89 zone, driving FY25 to $7.95 vs. the $7.86–$7.91 narrowed guide. The cushion management trimmed in Q3 turned out to be more than sufficient.

Resolved positively

HST organic growth as the Mott anniversary hits in Q4 2025. HST organic sales grew +5% YoY in Q4 (reported +9%, with FX and Micro-LAM contributing ~2pp each). Management's FY26 HST guide of "approximately mid-single digit growth" aligns with this clean organic base.

Resolved positively

Price contribution durability. Per CFO, FY25 price was ~3% (Q4 ~3.5%); FY26 price contribution is guided to 1–2%. Combined with the 1–2% FY26 organic guide, this implies roughly flat volumes overall — consistent with management's "no inflection" framing. Status: Resolved (decelerating)

Whether the $60M cost savings flow through to FY2026 margin guidance or get reinvested. Reinvested. The FY26 adjusted EBITDA margin guide of 26.5–27.0% brackets FY25's 26.8% actual. CFO disclosed that ~$20M of the $60M was temporary and is being allowed back into FY26 to fund growth-area reinvestment.

Resolved negatively

FSDP stabilization. FSDP organic sales declined 5% YoY in Q4, the second consecutive decline, and FY26 guidance formalizes the segment as "down" rather than transitory. Management's tone shifted from cyclical disruption to structural softness, with no recovery catalyst identified.

Resolved negatively

Buyback cadence vs. leverage. Q4 buyback was $73M ($75M settled cost, 0.4M shares) — matching the Q3 ~$75M pace. FY25 total: ~$248M / 1.4M shares. Gross leverage came down from 2.2x to 2.0x during the year. CFO described going-forward repurchases as a "base amount" flexed up based on leverage and M&A activity. Status: Resolved (sustained pace)

What to watch into next quarter

Does the Q2 sequential ramp materialize as guided? Management contemplates a typical low-to-mid-single-digit sequential sales step-up in Q2 with a more pronounced earnings step-up. If Q1 prints in line but Q2 ramp lags, the FY26 26.5–27.0% EBITDA band gets hard to defend.

HST organic growth post-Mott anniversary, clean. Q4 organic +5% with Mott now in the base — the FY26 mid-single-digit guide aligns. Whether Q1 sustains ≥5% organic at HST tests whether data-center backlog (~50% of build) is converting to revenue on schedule.

Q1 organic orders growth. Q4's +16% total / +34% HST organic orders is the lone real positive signal; management noted January order strength has continued. If Q1 orders sustain double-digit organic growth, the "no inflection" guide will look conservative. If they fade back toward low-single-digits, the FY26 1–2% organic sales guide is the ceiling, not the floor.

FSDP YoY trajectory. Third consecutive organic decline would confirm the structural read; a flat or positive print would force management to walk back the "down" segment framing.

Whether the FY26 EBITDA margin guide gets revised in either direction at Q1. Management has narrowed guidance within the year before (Q3 FY25); watch for either an early upward move on Q4 order conversion or a downward revision if Q1 margin disappoints.

Capital deployment cadence. With M&A formally deprioritized to bolt-ons and CFO defining buybacks as a "base amount" with flex, watch the Q1 repurchase dollar number against the ~$75M Q3/Q4 run-rate. Anything materially below signals deleveraging is taking priority over share repurchase.

Sources

IDEX Q4 FY2025 press release / 8-K exhibit 99.1: https://www.sec.gov/Archives/edgar/data/832101/000162828026005268/iex-20251231xex991.htm
IDEX Q4 FY2025 earnings conference call (prepared remarks and Q&A), February 4, 2026 — webcast and transcript via investors.idexcorp.com

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.